An interventional study of Rezūm Water Vapor Thermal Therapy and EchoLaser Transperineal Laser Ablation (TPLA) in Benign Prostatic Hyperplasia, sponsored by Benha University. Not yet recruiting. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Benha University · Not applicable, Interventional, and Treatment
This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe. The two treatments being compared are Rezūm (water vapor thermal therapy) and EchoLaser (transperineal laser ablation). Participants will be randomized into two equal groups to receive either the Rezūm treatment or the EchoLaser treatment. The primary goal of the study is to evaluate the change in urinary symptoms over a 6-month period using the International Prostate Symptom Score (IPSS). The study will also assess how well each treatment improves urine flow, reduces the size of the prostate, preserves sexual function, and minimizes complications.
This is a single-center, prospective, randomized, active-controlled trial aiming to compare the clinical efficacy, safety profile, and functional outcomes of Rezūm water vapor thermal therapy versus EchoLaser transperineal laser ablation (TPLA). The trial focuses on symptomatic benign prostatic hyperplasia patients with a prostate volume between 30 mL and 80 mL and a confirmed enlarged intravesical median lobe. Eighty eligible male patients will be randomized 1:1 into two interventional groups: Group 1 (Rezūm Group): 40 patients will receive transurethral water vapor thermal therapy. The procedure involves targeted 9-second steam injections into the transition zone, alongside mandatory injections directed explicitly into the intravesical protruding median lobe to induce coagulative necrosis. Group 2 (EchoLaser TPLA Group): 40 patients will receive Transperineal Laser Ablation. Under real-time transrectal ultrasound (TRUS) guidance, optical fibers will deliver continuous-wave diode laser energy (1064 nm) directly to the adenoma and the obstructing median lobe. Patients will undergo clinical, functional, and safety assessments at 1, 3, and 6 months post-operatively. Follow-up evaluations include uroflowmetry (peak urinary flow rate and post-void residual volume), symptom assessment via IPSS, and sexual health evaluation using IIEF-5 and MSHQ-EjD questionnaires. Morphological changes, specifically the reduction in Total Prostate Volume (TPV) and median lobe volume, will be confirmed using TRUS or mpMRI at the 6-month follow-up. Postoperative complications will be monitored and systematically graded using the Clavien-Dindo classification system.
783 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.
This study's planned enrollment of 80 is below the median of 97 across 593 interventional studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →Benha University is the lead sponsor of 356 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria:
Male patients aged 50 years or older.
Diagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12.
Total prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI.
Presence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy.
Peak urinary flow rate (Qmax) between 5 and 15 mL/s with a minimum voided volume of ≥ 125 mL.
Exclusion Criteria:
Confirmed or suspected prostate cancer (e.g., PSA > 4.0 ng/mL without a subsequent negative prostate biopsy or MRI).
History of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs).
Presence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction.
Active urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening.
Previous pelvic radiation therapy or severe pelvic trauma.
Inability to safely pause anticoagulant/antiplatelet therapy per standard hospital perioperative protocols, if applicable.
40 patients receiving transurethral water vapor thermal therapy (Rezūm). The procedure involves targeted 9-second steam injections into the transition zone and the median lobe.
Device: Rezūm Water Vapor Thermal Therapy
40 patients receiving Transperineal Laser Ablation utilizing the EchoLaser system. Optical fibers will deliver localized diode laser energy to the adenoma and the intravesical median lobe.
Device: EchoLaser Transperineal Laser Ablation (TPLA)
Conducted via a transurethral approach. Standard 9-second thermal water vapor injections will be delivered into the transition zone, alongside mandatory, specifically angled injections directed explicitly into the intravesical protruding median lobe to induce targeted coagulative necrosis.
Conducted via a transperineal approach. Under real-time transrectal ultrasound (TRUS) guidance, 21G introducer needles are placed, and optical fibers (300 µm) deliver continuous-wave diode laser energy (1064 nm) directly to the adenoma and the obstructing median lobe.
Change in International Prostate Symptom Score (IPSS)
The absolute and percentage difference in total IPSS, reflecting the primary subjective alleviation of lower urinary tract symptoms (LUTS).
Time frame: Baseline to 6 months
Change in Peak Urinary Flow Rate (Qmax)
Objective change in peak urinary flow rate, measured in mL/s using uroflowmetry.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Post-Void Residual Volume (PVR)
Objective change in post-void residual volume, measured in mL via abdominal ultrasound.
Time frame: Baseline, 1 month, 3 months, and 6 months
No study locations are listed for this record.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Benha University